Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation

2022914 citationsJournal Articlebronze Open Access

Authors

Pasi A. Jänne · Memorial Sloan Kettering Cancer Center

Gregory J. Riely · Memorial Sloan Kettering Cancer Center

Shirish M. Gadgeel · Memorial Sloan Kettering Cancer Center

Rebecca S. Heist · Memorial Sloan Kettering Cancer Center

Sai‐Hong Ignatius Ou · Memorial Sloan Kettering Cancer Center

Jose M. Pacheco · Memorial Sloan Kettering Cancer Center

Melissa L. Johnson

Abstract

In patients with previously treated KRASG12C -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. (Funded by Mirati Therapeutics; ClinicalTrials.gov number, NCT03785249.).

Topics & Keywords

Protein Kinase Regulation and GTPase Signaling Lung Cancer Treatments and Mutations PI3K/AKT/mTOR signaling in cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 387, Issue 2, pp. 120-131

DOI: 10.1056/nejmoa2204619

Field-Weighted Citation Impact: 73.74

Command Palette

Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS <sup>G12C</sup> </i> Mutation

Authors

Abstract

Topics & Keywords

UN Sustainable Development Goals

Publication Details